Published in Liver Int on March 16, 2011
A Prospective Cohort Study to Improve HCV Care in Dialysis Patients (MATCH-D) | NCT03791814
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology (2014) 3.04
Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.65
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep (2014) 1.55
Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon (2012) 1.47
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep (2012) 1.18
Current and future disease progression of the chronic HCV population in the United States. PLoS One (2013) 1.17
Best strategies for global HCV eradication. Liver Int (2013) 1.16
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol (2013) 1.00
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology (2014) 0.99
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol (2015) 0.97
Gene expression analysis in serial liver fine needle aspirates. J Viral Hepat (2014) 0.93
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis (2013) 0.93
Estimating the prevalence of hepatitis C infection in New York City using surveillance data. Epidemiol Infect (2013) 0.93
The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer (2012) 0.93
Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep (2014) 0.91
Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med (2015) 0.90
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis (2013) 0.90
The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat (2016) 0.89
Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. N Am J Med Sci (Boston) (2014) 0.88
Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. Open Forum Infect Dis (2015) 0.87
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol (2016) 0.87
Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study. BMC Infect Dis (2014) 0.86
Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol (2015) 0.86
Hepatitis C screening trends in a large integrated health system. Am J Med (2014) 0.86
Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems. Am J Public Health (2013) 0.85
Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread. J Virol (2014) 0.85
Survey of US Correctional Institutions for Routine HCV Testing. Am J Public Health (2015) 0.84
Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health (2014) 0.84
Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. J Clin Virol (2014) 0.84
Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open (2014) 0.84
Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother (2013) 0.83
Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin Infect Dis (2012) 0.83
Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. Dig Dis Sci (2014) 0.83
Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations. Antimicrob Agents Chemother (2013) 0.83
A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. J Public Health (Oxf) (2015) 0.83
Hepatitis C screening. Ochsner J (2014) 0.83
Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2016) 0.83
Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis (2016) 0.83
Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol (2015) 0.82
Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol (2015) 0.82
Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. Public Health Rep (2016) 0.82
Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. Dig Dis Sci (2015) 0.82
Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009. PLoS One (2015) 0.82
Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med (2014) 0.81
Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther (2013) 0.81
Recent advances in management of the HIV/HCV coinfected patient. Future Virol (2016) 0.81
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clin Infect Dis (2015) 0.81
Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system. J Urban Health (2015) 0.80
Hepatitis C Infection in the Elderly. Dig Dis Sci (2015) 0.80
Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf (2014) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int (2016) 0.79
Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N Y) (2014) 0.79
Hepatitis C virus testing in adults living with HIV: a need for improved screening efforts. PLoS One (2014) 0.79
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology (2015) 0.79
Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase Allosterically Block the Transition from Initiation to Elongation. J Biol Chem (2016) 0.79
A Smartphone Application Supporting Recovery from Heroin Addiction: Perspectives of Patients and Providers in China, Taiwan, and the USA. J Neuroimmune Pharmacol (2016) 0.78
Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. Clin Infect Dis (2016) 0.78
Hepatitis C virus-specific immune responses in noninjecting drug users. J Viral Hepat (2012) 0.78
Assessment of hepatitis C risk factors and infection prevalence in a jail population. Am J Public Health (2014) 0.78
A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System. J Urban Health (2015) 0.78
Age cohort differences in illicit drug use and hepatitis C among African American substance users. J Addict Dis (2014) 0.77
Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response. Hawaii J Med Public Health (2015) 0.77
Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract (2013) 0.77
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P T (2014) 0.77
Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye? Clin Infect Dis (2013) 0.77
Estimating the true prevalence of hepatitis C in rhode island. R I Med J (2013) (2014) 0.77
Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City. J Community Health (2014) 0.77
The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan. Drug Alcohol Depend (2013) 0.76
Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol (2014) 0.76
Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment. J Immunol Res (2015) 0.76
Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol (2016) 0.76
Hepatitis C viremia is associated with cytomegalovirus IgG antibody levels in HIV-infected women. PLoS One (2013) 0.75
Disparities in hepatitis C testing in U.S. veterans born 1945-1965. J Hepatol (2016) 0.75
Outlier populations: individual and social network correlates of solvent-using injection drug users. PLoS One (2014) 0.75
Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer (2016) 0.75
Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol (2015) 0.75
Cocaine Use May be Associated with Increased Depression in Persons Infected with HIV. AIDS Behav (2016) 0.75
Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors. Antivir Ther (2015) 0.75
Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment. Open Forum Infect Dis (2015) 0.75
Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore) (2016) 0.75
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. Drug Des Devel Ther (2016) 0.75
A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study. BMC Infect Dis (2015) 0.75
Performance of Risk-Based and Birth-Cohort Strategies for Identifying Hepatitis C Virus Infection Among People Entering Prison, Wisconsin, 2014. Public Health Rep (2016) 0.75
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D (2015) 0.75
Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. J Clin Transl Hepatol (2017) 0.75
Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico. P R Health Sci J (2014) 0.75
HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. Am J Prev Med (2015) 0.75
Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. J Community Health (2015) 0.75
Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan. PLoS One (2016) 0.75
Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment. Gastroenterol Hepatol (N Y) (2014) 0.75
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl (2002) 2.98
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol (2010) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Ammonia levels and the severity of hepatic encephalopathy. Am J Med (2003) 2.14
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology (2004) 1.80
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl (2009) 1.67
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.65
Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc (2010) 1.65
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl (2008) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology (2010) 1.56
Treating hepatitis C in the prison population is cost-saving. Hepatology (2008) 1.50
The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology (2006) 1.49
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr (2006) 1.44
Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol (2009) 1.42
Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci (2008) 1.38
Kidney transplantation threshold in patients with hepatitis C: a decision analysis model. Transplantation (2015) 1.38
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38
Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology (2006) 1.38
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.37
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis (2009) 1.36
Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf (2007) 1.36
Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology (2004) 1.36
Treatment of hepatitis C. Am J Med (2005) 1.35
Alcohol and hepatitis C. Semin Liver Dis (2004) 1.34
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2003) 1.33
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis (2005) 1.31
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2007) 1.30
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann Surg (2010) 1.28
Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation. Transplantation (2007) 1.26
HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS (2011) 1.23
Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22
The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol (2006) 1.21
Postresection hepatic failure: successful treatment with liver transplantation. Liver Transpl (2007) 1.20
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol (2003) 1.19
Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology (2004) 1.19
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis (2003) 1.18
Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol (2011) 1.18
The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis (2011) 1.17
Viral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol (2009) 1.17
The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology (2014) 1.17
Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology (2005) 1.15
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg (2003) 1.15
Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis (2004) 1.14
Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int (2010) 1.14
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol (2007) 1.13
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis (2005) 1.12
Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl (2004) 1.12
Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults. Nurs Res (2008) 1.11
Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc (2002) 1.11
The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) (2011) 1.11
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg (2013) 1.08
HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood (2004) 1.08
Clinical application of polymerase chain reaction to diagnose Clostridium difficile in hospitalized patients with diarrhea. Clin Gastroenterol Hepatol (2004) 1.07
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.07
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology (2006) 1.07
Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc (2010) 1.06
Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci (2010) 1.06
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis (2011) 1.04